RIO DE JANEIRO, BRAZIL – Preliminary results of a research conducted by the Vebra Covid-19 group released on Wednesday, March 7, pointed out that CoronaVac – the most used vaccine in Brazil today – is 50% effective against symptomatic cases of infection by the P.1 variant, the one from Manaus, also called the Brazilian variant. The positive results are observed 14 days after the first dose of the immunization.
The study involved 67,718 health workers in the capital of the state of Amazonas, where the P.1 mutation is prevalent, says the researchers’ statement. The same material points out that these findings support this vaccine’s continued use in Brazil and other countries with circulation of the same strain.
However, it is still necessary to gather more information to evaluate the effectiveness of the second dose. Previous analyses, preliminarily released by the Butantan Institute, responsible for the vaccine’s operationalization in Brazil, also indicated that the vaccine is effective against the Manaus variant.
The CoronaVac vaccine was developed by the Chinese pharmaceutical company Sinovac Life Science in partnership with the São Paulo government controlled Butantan Institute.
Source: Veja